scorecardresearch
Friday, March 29, 2024
Support Our Journalism
HomeHealthExpert panel seeks additional data on Covid vaccines from Serum Institute, Bharat...

Expert panel seeks additional data on Covid vaccines from Serum Institute, Bharat Biotech

The applications of Bharat Biotech and Serum Institute of India are under consideration, while that of the Indian arm of Pfizer has not yet been taken up.

Follow Us :
Text Size:

New Delhi: An expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data for COVID-19 vaccine candidates of Serum Institute and Bharat Biotech, after deliberating upon their applications seeking emergency use authorisation for the shots, official sources said.

The application by the Indian arm of US pharmaceutical firm Pfizer was not taken up for deliberation on Wednesday as the firm sought more time for making presentation before the committee, they said.

The applications of both Bharat Biotech and the Serum Institute of India are still under consideration, a source told PTI.

While considering Serum Institute’s application, the subject expert committee (SEC) of the CDSCO is learnt to have asked for updated safety data of phase-2 and phase-3 clinical trials in the country, immunogenicity data from the clinical trial in the UK and India, along with the outcome of the assessment of the UK Medicines and Healthcare products Regulatory Agency (MHRA), sources said.

As for Hyderabad-based Bharat Biotech, after detailed deliberations, the SEC recommended that the firm should present the safety and efficacy data from the ongoing phase-3 clinical trial in the country for further consideration, the source said.

Bharat Biotech had applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed COVID-19 vaccine Covaxin on December 7, while Pune-based Serum Institute sought the nod for the Oxford COVID-19 vaccine, Covishield, on December 6.

Pfizer had applied for emergency use authorisation for its vaccine on December 4.-PTI


Also read: UK warns those with severe allergy shouldn’t get Pfizer Covid vaccine


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular